PRDX1 and acute myeloid leukemia: Furthermore, targeting PRDX1 with lentiviral short-hairpin RNAs (shRNA) or TH37 enhanced the effects of conventional chemotherapeutic drugs, underscoring the potential of TH37 to improve existing treatment strategies for AML.